Skip to main content

Catalyst Calendar

Mon, Aug 10, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

Trial Start • Phase 2Trial initiation Mon, Jun 1, 2026, 7:00 AM EDTtonixpharma.com

Wed, Aug 5, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

tonixpharma.com

Mon, Aug 3, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

tonixpharma.com

Mon, Jul 27, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

tonixpharma.com

Wed, Jul 15, 2026

1 updates

9:05 AM

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

tonixpharma.com

Mon, Jul 13, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

tonixpharma.com

Mon, Jun 29, 2026

1 updates

7:25 AM

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

Trial Start • Phase 2Trial initiation Mon, Jun 29, 2026, 7:25 AM EDTtonixpharma.com

Thu, Jun 11, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

tonixpharma.com

Mon, Jun 8, 2026

1 updates

7:00 AM

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

tonixpharma.com